Will Champions Oncology (NASDAQ:CSBR) Spend Its Cash Wisely?
Champions Oncology Cut to Hold From Buy by Craig-Hallum
Champions Oncology Cut to Hold From Buy by Craig-Hallum
Craig-Hallum Downgrades Champions Oncology to Hold
Craig-Hallum analyst Matt Hewitt downgrades Champions Oncology from Buy to Hold.
Champions Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 — Craig-Hallum Downgrades Buy → Hold 09/22/2023 32.74% Roth MKM $9 → $7.5 Maintains Buy 03/15/
Earnings Call Summary | Champions Oncology(CSBR.US) Q3 2024 Earnings Conference
The following is a summary of the Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript:Financial Performance:Champions Oncology reported Q3 revenue of $12 million, a 6% decline compared to
Champions Oncology Non-GAAP EPS of -$0.16, Revenue of $12M
Champions Oncology: Q3 Earnings Insights
Champions Oncology (NASDAQ:CSBR) reported its Q3 earnings results on Tuesday, March 12, 2024 at 04:00 PM.Here's what investors need to know about the announcement.EarningsChampions Oncology missed est
Champions Oncology Q3 Adj $(0.16) Misses $(0.15) Estimate, Sales $12.02M Miss $13.48M Estimate
Champions Oncology (NASDAQ:CSBR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is unchanged from the same period last year
Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today ann
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. • MINISO Group Holding (NYSE:MNSO) is likely to report quarterly earnings at $0.27
Earnings Outlook For Champions Oncology
Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Here's what investors need to know before the announcement.Analysts estimate that Champions
Craig-Hallum Gives a Buy Rating to Champions Oncology (CSBR)
Champions Oncology's US Laboratory Has Acquired Distinguished CAP Accreditation
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced that the College of
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and
Analysts' Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Champions Oncology (CSBR)
Champions Oncology(CSBR.US) Director Buys US$6,500 in Common Stocks
$Champions Oncology(CSBR.US)$ Director Mendelson Daniel Newman purchased 1,000 shares of Common Stocks on Jan 12, 2024 at an average price of $6.5 for a total value of $6,500.Source: Announcement What
Champions Oncology(CSBR.US) Director Buys US$12,540 in Common Stocks
$Champions Oncology(CSBR.US)$ Director Mendelson Daniel Newman purchased 2,000 shares of Common Stocks on Jan 11, 2024 at an average price of $6.27 for a total value of $12,540.Source: Announcement Wh
Champions Oncology(CSBR.US) Director Buys US$18,576.64 in Common Stocks
$Champions Oncology(CSBR.US)$ Director Mendelson Daniel Newman purchased 2,944 shares of Common Stocks on Jan 10, 2024 at an average price of $6.31 for a total value of $18,576.64.Source: Announcement
Champions Oncology(CSBR.US) Director Buys US$18,750 in Common Stocks
$Champions Oncology(CSBR.US)$ Director Mendelson Daniel Newman purchased 3,000 shares of Common Stocks on Jan 9, 2024 at an average price of $6.25 for a total value of $18,750.Source: Announcement Wha
Insiders Buying Tilly's And 2 Other Stocks
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
No Data